Research location
Berlin
New Jersey, United States
Advertisement
Research activity in Berlin
New Jersey, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 209 trials and 210 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Berlin
209 linked trials · page 1 of 5An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.NCT07543120 · 2026-05-07 · 1 site observation
RECRUITING
A Study of CX11 Tablets in Patients With Type 2 Diabetes MellitusNCT07340320 · 2026-02-06 · 1 site observation
RECRUITING
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)NCT06633016 · 2024-09-20 · 1 site observation
RECRUITING
GV101 in Healthy Obese ParticipantsNCT06979505 · 2025-06-30 · 1 site observation
COMPLETED
A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)NCT06941844 · 2025-04-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive PatientsNCT06857955 · 2025-03-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DMNCT06897202 · 2025-03-14 · 1 site observation
COMPLETED
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass PreservationNCT06299098 · 2024-03-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)NCT06272487 · 2024-02-29 · 1 site observation
COMPLETED
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive DisorderNCT06058039 · 2023-12-21 · 1 site observation
COMPLETED
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute SchizophreniaNCT06179108 · 2023-11-29 · 1 site observation
COMPLETED
Study to Assess the Safety and Effectiveness of NMRA-335140-501NCT06029439 · 2023-11-10 · 1 site observation
TERMINATED
A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate ADNCT05686044 · 2023-04-01 · 1 site observation
COMPLETED
An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic MedicationNCT05741528 · 2023-03-31 · 1 site observation
COMPLETED
Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary FunctionNCT05625347 · 2023-03-11 · 1 site observation
TERMINATED
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DMNCT05761301 · 2023-03-10 · 1 site observation
TERMINATED
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)NCT05686408 · 2023-03-02 · 1 site observation
COMPLETED
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic MedicationNCT05628103 · 2022-12-19 · 1 site observation
COMPLETED
A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)NCT05686239 · 2022-12-08 · 1 site observation
COMPLETED
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)NCT05658510 · 2022-11-21 · 1 site observation
COMPLETED
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With ObesityNCT05579977 · 2022-10-27 · 1 site observation
TERMINATED
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With SchizophreniaNCT05545111 · 2022-10-04 · 1 site observation
COMPLETED
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease AgitationNCT05557409 · 2022-09-06 · 1 site observation
COMPLETED
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With SchizophreniaNCT05443724 · 2022-09-01 · 1 site observation
TERMINATED
A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaNCT05227703 · 2022-07-05 · 1 site observation
COMPLETED
Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female VolunteersNCT05438303 · 2022-06-13 · 1 site observation
COMPLETED
A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 DiabetesNCT05377333 · 2022-06-02 · 1 site observation
COMPLETED
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPDNCT04320342 · 2022-04-27 · 1 site observation
COMPLETED
Efficacy and Safety of ALT-801 in the Treatment of ObesityNCT05295875 · 2022-03-31 · 1 site observation
COMPLETED
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaNCT05304767 · 2022-03-07 · 1 site observation
COMPLETED
Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes MellitusNCT05114590 · 2022-01-27 · 1 site observation
COMPLETED
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaNCT05145413 · 2021-11-12 · 1 site observation
COMPLETED
An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderNCT05061719 · 2021-10-08 · 1 site observation
COMPLETED
CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With SchizophreniaNCT04860830 · 2021-08-09 · 1 site observation
COMPLETED
Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderNCT04985942 · 2021-07-30 · 1 site observation
COMPLETED
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive MedicationNCT04937829 · 2021-07-20 · 1 site observation
COMPLETED
Lumateperone for the Prevention of Relapse in Patients With SchizophreniaNCT04959032 · 2021-07-08 · 1 site observation
COMPLETED
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)NCT04820309 · 2021-06-02 · 2 site observations
COMPLETED
Investigational Study of Delayed Release MetforminNCT04854512 · 2021-05-18 · 1 site observation
SUSPENDED
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)NCT04738123 · 2021-04-06 · 1 site observation
COMPLETED
A Clinical Trial of PRAX-114 in Participants With Major Depressive DisorderNCT04832425 · 2021-03-30 · 1 site observation
COMPLETED
Comparative Bioavailability of Risperidone.NCT05179525 · 2021-03-09 · 1 site observation
COMPLETED
An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)NCT04659174 · 2021-02-01 · 1 site observation
COMPLETED
Relative Bioavailability of LY03010 Compared to Listed DrugNCT04922593 · 2021-01-13 · 1 site observation
COMPLETED
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive DisorderNCT04479852 · 2020-09-30 · 1 site observation
COMPLETED
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)NCT04634669 · 2020-09-23 · 1 site observation
TERMINATED
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With SeltorexantNCT04533529 · 2020-09-16 · 1 site observation
COMPLETED
Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic PainNCT04455633 · 2020-09-03 · 1 site observation
COMPLETED
Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)NCT04506905 · 2020-08-28 · 1 site observation
COMPLETED
Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic TreatmentNCT04421456 · 2020-08-18 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.